// App-Quantinova.ai

: Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist

Researchers

Presenter

  • Lorcan McGarvey

Principal Investigators

  • Jaclyn Smith

  • Surinder Birring

  • Alyn Morice

  • Mandel Sher

  • Wen-Chi Wu

  • David Muccino

Medical Centers

  • Centre for Experimental Medicine, Queen's University Belfast, Belfast, United Kingdom

  • Immunity and Respiratory Medicine, University of Manchester, Manchester, United Kingdom

  • Kings College London, London, United Kingdom

  • The Hull York Medical School, Cottingham, United Kingdom

  • Center for Cough, Largo, Largo, FL, United States of America

  • Merck & Co., Inc., Kenilworth, United States of America

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • X-Ray Repair Cross Complementing 1

Drug/Treatment

  • Gefapixant

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Parallel Group

Phase

  • II

Study Id's

  • NCT02612610

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved